Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
botulinum toxin type b
- Development stage
- Approved
- Lead developer
- US WorldMeds
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Botulinum toxin type B is a purified neurotoxin produced by fermentation of Clostridium botulinum type B. It is used primarily to treat cervical dystonia (a neurological disorder characterized by involuntary contractions of the neck and/or shoulder muscles) and sialorrhea. The drug acts at the neuromuscular junction to produce flaccid paralysis by inhibiting acetylcholine release. Its mechanism involves binding to synaptic vesicle-associated membrane protein (VAMP/synaptobrevin), which prevents neurotransmitter release through cleavage of essential polypeptides for vesicle docking and fusion. Botulinum toxin type B is marketed under brand names such as Myobloc (in the US) and NeuroBloc (in Europe). It has demonstrated efficacy in patients with cervical dystonia, including those resistant to botulinum toxin A[1][3][5][8].
- Brand names
- MyoblocNeuroBloc
- Other names
- botulinum toxin type brimabotulinumtoxinb
02
Targets
SYT2 (Synaptotagmin-2)VAMP2 (Vesicle-associated membrane protein 2)VAMP1 (Vesicle-associated membrane protein 1)
Beyond the preview
Go deeper on botulinum toxin type b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on botulinum toxin type b.